Comments on "effective dose 50% (ED50) and effective dose 95% (ED95) of intrathecal bupivacaine in morbidly obese patients undergoing cesarean delivery"

1. Carvalho B, Collins J, Drover DR, Atkinson Ralls L, Riley ET. ED(50) and ED(95) of intrathecal bupivacaine in morbidly obese patients undergoing cesarean delivery. Anesthesiology. 2011;114:529-35.

2. D'Angelo R, Dewan D. Obesity. In: Chestnut D, Polley L, Tsen L, Wong C, editors. Chestnut's obstetric anesthesia: principles and practice. 4th ed. Philadelphia, PA: Mosby Elsevier; 2009. p. 1079-93.

3. Hogan QH, Prost R, Kulier A, Taylor ML, Liu S, Mark L. Magnetic resonance imaging of cerebrospinal fluid volume and the influence of body habitus and abdominal pressure. Anesthesiology. 1996;84:1341-9.

4. Norris MC. Height, weight, and the spread of subarachnoid hyperbaric bupivacaine in the term parturient. Anesth Analg. 1988;67:555-8.

5. Norris MC. Patient variables and the subarachnoid spread of hyperbaric bupivacaine in the term parturient. Anesthesiology. 1990;72:478-82.

6. Ginosar Y, Mirikatani E, Drover DR, Cohen SE, Riley ET. ED50 and ED95 of intrathecal hyperbaric bupivacaine coadministered with opioids for cesarean delivery. Anesthesiology. 2004;100:676-82.

7. Lee Y, Balki M, Parkes R, Carvalho JC. Dose requirement of intrathecal bupivacaine for cesarean delivery is similar in obese and normal weight women. Rev Bras Anestesiol. 2009;59:674-83.

8. Arzola C, Wieczorek PM. Efficacy of low-dose bupivacaine in spinal anaesthesia for caesarean delivery: systematic review and meta-analysis. Br J Anaesth. 2011;107:308-18.

9. Einhorn L, Akushevich I, Habib A. Intrathecal bupivacaine dose for cesarean delivery is not reduced in obese compared to non-obese parturients. In: ASA Meeting. 2014. p. A4206.